Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 500 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all

Conditions: Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions: GlucoSTAT; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: teplizumab; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 0 Years to 7 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Simvastatin, PF-05175157; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, exenatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 76
States / cities: Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 39
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more

Conditions: Diabetes Mellitus, Type II
Interventions: HM-002-1005; Drug
Lead sponsor: Hua Medicine Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Type 2 Diabetes, Cardiovascular Risk
Interventions: Zenagamtide, Insulin glargine U-100; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 109
States / cities: Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more

Conditions: Diabetes Mellitus Type 2 in Obese
Interventions: standard of care in general clinical practice; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 24 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 16
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT); Drug · Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
Interventions: metformin, placebo, Sitagliptin; Drug
Lead sponsor: Dawn Smiley MD; Other
Eligibility: 19 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer Due to Type 1 Diabetes Mellitus, Diabetic Foot Ulcer
Interventions: XWRAP; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: aflibercept, High-dose aflibercept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 84
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acromegaly, Type 2 Diabetes Mellitus
Interventions: Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes
Interventions: Subcutaneous glucose monitoring device; Device
Lead sponsor: BioTex, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 29
States / cities: Little Rock, Arkansas • Escondido, California • Goleta, California + 25 more

Conditions: Diabetes, Hypoglycemia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 90 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes
Interventions: BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type 1, Type 2
Interventions: Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Burlingame, California • Tallahassee, Florida

Conditions: Healthy, Type 2 Diabetes Mellitus
Interventions: LY3938577, Placebo, Insulin degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Dallas, Texas

Conditions: Diabetes, Insulin
Interventions: insulin dose software; Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 21 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus
Interventions: non-invasive tissue glucose prediction; Device
Lead sponsor: Sciema UG; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Search by objective public record fields.

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Hypoglycemia in Hospitalized Patients

A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

Green Digital Diabetes Waste Project

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

Use of CoG by Patients With Diabetes Mellitus